metabolic syndrome. Metabolic syndrome
Conditions
Interventions
Intervention 1: Intervention group:daily intake of 400µg of trivalent chromium picolinate tablets (21 st CENTURY, US company) for 12 weeks. Intervention 2: Control group: daily intake of matched p
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Metabolic syndrome characterized by"at least three of the five conditions: - waist circumference =94 cm - systolic blood pressure and diastolic greater than or equal to 130 and 85 mm Hg respectively or blood pressure lowering medication use - Fasting Blood Sugar= 100 mg / dl or hypoglycemic drugs use - Blood triglycerides =150 mg / dl or lipid-lowering drugs use - HDL<50mg/dl in women and less than 40 mg/ dl in Men"
Exclusion criteria
Exclusion criteria: take any multivitamins or dietary supplements or medications Pregnancy or lactation uncontrolled hypertension or hyperglycemia chronic obstructive pulmonary disease heart arrhythmias stroke any other disease that requires medical treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycemic Index(Fasting Blood Sugar, Glycosylated Hemoglobin). Timepoint: Beginning of the study and at the end of the study (end of the fourth month). Method of measurement: enzymatic colorimetric method.;Lipid Profile(TG, TC, LDL ,HDL). Timepoint: Beginning of the study and at the end of the study (end of the fourth month). Method of measurement: enzymatic colorimetric method.;DNA damage(hydroxy-deoxyguanosine). Timepoint: Beginning of the study and at the end of the study (end of the fourth month). Method of measurement: Enzyme Linked Immunosorbent Assay (ELISA).;Interleukin-1. Timepoint: Beginning of the study and at the end of the study (end of the fourth month). Method of measurement: Enzyme Linked Immunosorbent Assay (ELISA).;Interleukin-6. Timepoint: Beginning of the study and at the end of the study (end of the fourth month). Method of measurement: Enzyme Linked Immunosorbent Assay (ELISA).;Tumor Necrosing Factor-a. Timepoint: Beginning of the study and at the end of the study (end of the fourth month). Method of measurement: Enzyme Linked Immunosorbent Assay (ELISA).;Gene Expression of Inflammatory Biomarkers (Tumor Necrosing Factor-a). Timepoint: Beginning of the study and at the end of the study (end of the fourth month). Method of measurement: reverse transcription polymerase chain (RT-PCR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: The beginning of the study and the end of the fourth month. Method of measurement: standard scale.;Waist circumference. Timepoint: The beginning of the study and the end of the fourth month. Method of measurement: non-stretching tape.;Blood pressure. Timepoint: The beginning of the study and the end of the fourth month. Method of measurement: Blood pressure monitor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehrooz Ebrahimzadehkoor
Yasouj University of Medical Sciences
Outcome results
None listed